logo Hematology/Oncology Research Studies: Open for Enrollment Date: 10/22/18

Category: STEM CELL TRANSPLANTATION AND CELLULAR THERAPY

Pediatric and Young Adult Leukemia Adoptive Therapy. A Phase 1/2 Feasibility and Safety Study of CD19-CAR T Cell Immunotherapy for CD19+ Leukemia

NCT#/Phase: NCT02028455
Phase 1/2
IRB#: 2017-053
Description: This study will evaluate the safety, toxicity and efficacy of cellular immunotherapy utilizing ex-vivo expanded patient-derived T cells that have been genetically modified to express a CD19-specific chimeric antigen receptor (CAR).
Inclusion: Individuals who are between 1 - 27 years of age with recurrent CD19+ leukemia or lymphoma.
Enrollment Status: Open for enrollment
Sponsor: Seattle Children's Hospital
Principal Investigator(s): Anu Agrawal, MD
Contact(s): Marci Moriarty, RN (510-428-3385 x5396)
Julie Decaris (510-428-3385 x2739)
Study Link: https://clinicaltrials.gov/ct2/show/NCT02028455

UCSF Benioff Children's Hospital Oakland • 747 52nd Street, Oakland, California 94609 &bull Phone: (510) 428-3000